However, postadolescent patients with manifest Wolff-Parkinson-White syndrome (in whom atrial fibrillation becomes more likely) should not receive digoxin or a nondihydropyridine calcium channel blocker alone (see also Atrial Fibrillation and Wolff-Parkinson-White Syndrome).